Casdin Capital’s Wave Life Sciences WVE Stock Holding History

Casdin Capital’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$1.4M	–	48
2022 Q4	$1.4M	Buy	+200,000	New	+$922K	0.11%	43

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Casdin Capital's WVE Position: Q1 2023 in Review

Casdin Capital sold out of Wave Life Sciences (WVE) in Q1 2023, closing a stake of 200,000 shares — an estimated $1.4M sold.

Casdin Capital first reported a position in WVE in Q4 2022 and held it in 1 quarter. The position peaked at $1.4M in Q4 2022. 72 funds tracked by Wall St. Rank hold WVE as of Q1 2023.

Casdin Capital reported no remaining Wave Life Sciences position as of Q1 2023 after selling out during the quarter.
Casdin Capital sold 200,000 Wave Life Sciences shares in Q1 2023, an estimated $1.4M.
Casdin Capital first reported a position in Wave Life Sciences in Q4 2022 and held it in 1 quarter.
Casdin Capital's Wave Life Sciences position peaked at $1.4M in Q4 2022.
72 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2023.

Based on Casdin Capital's 13F filing for Q1 2023, filed 15 May 2023.